Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRVS
STRONG SELLCorvus Pharmaceuticals, Inc. · Healthcare · United States · $1.1B · Avg Vol: $17M/d
COMPANY DESCRIPTION
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel, first-in-class immunotherapies for the treatment of cancer and autoimmune diseases. The company's competitive moat is centered on its proprietary pipeline of small molecules and antibodies, most notably soquelitinib, a selective ITK inhibitor designed to reprogram T-cells to fight tumors. By targeting unique immunological pathways, Corvus aims to address significant unmet needs in oncology and immunology with highly differentiated therapeutic candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 5.7M | — |
| EPS | -0.89 | -0.56 | -1.02 | -0.19 | — | -0.52 | -0.72 | -0.95 | — |
| Shares | 46.6M | 49.0M | 67.9M | 74.7M | +60.5% | 84.1M | — | — | — |
| Debt | 2.6M | 1.4M | 1.1M | 0.9M | -28.8% | 0.8M | — | — | — |
| Equity | 56.1M | 38.7M | 32.6M | 61.2M | 2.9% | — | — | — | — |
| Op CF | -27.0M | -23.9M | -25.4M | -32.8M | — | -34.9M | — | — | — |
| Inv CF | -23.3M | 15.5M | -27.5M | -7.8M | — | — | — | — | — |
| Fin CF | 0 | 7.9M | 49.0M | 36.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc.(you) | $1.1B | 11 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 11 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
| AKTS | Aktis Oncology, Inc. | $1.3B | 10 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
| VOR | Vor Biopharma Inc. | $1.0B | 14 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 10 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.2B | 7 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%